Drug Trial Radar · NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Mar 16, 2025
Primary completion
May 18, 2030
Study completion May 18, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Conditions
- Triple Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecanBiological
IV Infusion
PembrolizumabBiological
IV Infusion
Rescue MedicationDrug
Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
PaclitaxelDrug
IV Infusion
Nab-paclitaxelDrug
IV Infusion
GemcitabineDrug
IV Infusion
CarboplatinDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) (sac-TMT versus treatment of physician's choice (TPC); sac-TMT plus pembrolizumab versus TPC)Time frame: Up to ~39 months
- Overall Survival (OS) (sac-TMT versus TPC)Time frame: Up to ~61 months
Locations
285 sites in 35 countries. Site status is shown where the registry gives one.
USA Mitchell Cancer Institute ( Site 0090)
Mobile, Alabama · Recruiting
Ironwood Cancer & Research Centers ( Site 0036)
Chandler, Arizona · Recruiting
City of Hope ( Site 0097)
Duarte, California · Recruiting
City of Hope Lennar Foundation Cancer Center ( Site 0099)
Irvine, California · Recruiting
UCLA Department of Medicine - Hematology & Oncology ( Site 0047)
Los Angeles, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016)
San Francisco, California · Recruiting
Yale New Haven Hospital ( Site 0001)
New Haven, Connecticut · Completed
Washington Hospital Center ( Site 0098)
Washington D.C., District of Columbia · Recruiting
AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007)
Altamonte Springs, Florida · Recruiting
Orlando Health Cancer Institute ( Site 0012)
Orlando, Florida · Recruiting
Florida Cancer Specialists - East ( Site 7000)
West Palm Beach, Florida · Recruiting
University Cancer & Blood Center, LLC ( Site 0023)
Athens, Georgia · Recruiting
St. Luke's Cancer Institute: Boise ( Site 0037)
Boise, Idaho · Recruiting
University of Illinois Cancer Center ( Site 0044)
Chicago, Illinois · Recruiting
MedStar Franklin Square Medical Center ( Site 0031)
Baltimore, Maryland · Recruiting
MedStar Good Samaritan Hospital ( Site 0079)
Baltimore, Maryland · Recruiting
MedStar Southern Maryland Hospital Center ( Site 0100)
Clinton, Maryland · Recruiting
MedStar Montgomery Medical Center ( Site 0078)
Olney, Maryland · Recruiting
Holy Cross Hospital ( Site 0091)
Silver Spring, Maryland · Recruiting
Cancer & Hematology Centers of Western Michigan ( Site 0026)
Grand Rapids, Michigan · Recruiting
Allina Health Cancer Institute ( Site 0069)
Minneapolis, Minnesota · Completed
Hattiesburg Clinic Hematology/Oncology ( Site 0104)
Hattiesburg, Mississippi · Recruiting
Comprehensive Cancer Centers of Nevada ( Site 0015)
Las Vegas, Nevada · Recruiting
Renown Regional Medical Center ( Site 0005)
Reno, Nevada · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0082)
Hackensack, New Jersey · Recruiting
New Mexico Oncology Hematology Consultants Ltd. ( Site 0019)
Albuquerque, New Mexico · Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073)
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center ( Site 0003)
New York, New York · Recruiting
Rex Hematology Oncology Associates - Garner ( Site 0071)
Garner, North Carolina · Completed
SCRI Oncology Partners ( Site 7004)
Nashville, Tennessee · Recruiting
Tennessee Oncology ( Site 0018)
Nashville, Tennessee · Recruiting
Texas Oncology - DFW ( Site 8007)
Dallas, Texas · Recruiting
Texas Oncology - West Texas ( Site 8004)
El Paso, Texas · Recruiting
Kelsey-Seybold Clinic - North Houston Campus ( Site 0096)
Houston, Texas · Recruiting
Kelsey-Seybold Clinic ( Site 0040)
Houston, Texas · Recruiting
Texas Oncology - San Antonio ( Site 8001)
San Antonio, Texas · Recruiting
University of Utah, Huntsman Cancer Institute ( Site 0056)
Salt Lake City, Utah · Recruiting
Virginia Oncology Associates (VOA) ( Site 8002)
Norfolk, Virginia · Recruiting
Fred Hutchinson Cancer Center ( Site 0042)
Seattle, Washington · Recruiting
Fundacion Centro Oncologico de Integración Regional ( Site 2400)
Mendoza, Argentina · Recruiting
Showing 40 of 285 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.